Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Cory Kasimov
Evercore ISI Institutional Equities, Research Division

Good afternoon, everybody. My name is Cory Kasimov, one of the senior biotech analysts here at Evercore ISI. And it’s my pleasure to host our next discussion with Regeneron. We’re fortunate to have both Marion McCourt, who heads up Commercial; as well as Ryan Crowe, SVP of IR and Strategic Analysis. And we have them for a full 45 minutes, which I’m sure you guys are thrilled about. In all seriousness, thank you both very much for being here today. And Ryan, I guess let me hand it over to you first, read off your little thing, and then we’ll get going.

Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis

I’ll read my little thing. But first, I will say thank you, Cory, and to Evercore for having us here. Great conference, as always, and a lot of great meetings so far. So excited to do this fireside chat with you, even though it is an extended version of a typical fireside chat. But without further ado, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. We’re ready to go into questions, Cory.